TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Candel Therapeutics
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Candel Therapeutics presented three key research presentations at SITC 2025, highlighting advances in immunotherapy for solid tumors using multi-omics analysis and artificial intelligence, including promising phase 3 clinical trial results for CAN-2409 in prostate cancer and preclinical data from their enLIGHTEN™ Discovery Platform.

Insights
CADL   positive

Demonstrated leadership in immunotherapy research, presented successful phase 3 clinical trial results, showcased innovative AI-driven discovery platform, and highlighted potential for novel cancer treatments across multiple tumor types